Iovance Biotherapeutics to Present at Upcoming Conference
Iovance Biotherapeutics announced that its Interim CEO and CFO will participate in a fireside chat at the upcoming 2026 Jefferies Global Healthcare Conference. The company specializes in novel tumor infiltrating lymphocyte (TIL) therapies for cancer and recently achieved FDA approval for Amtagvi, its T cell therapy for solid tumors.